{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:22:12Z","timestamp":1794651732867,"version":"4.9.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>While the molecular and genetic bases of Von Hippel\u2013Lindau (VHL) disease have been extensively investigated, limited evidence is available to guide diagnosis, local or systemic therapy, and follow-up. The aim of the current review is to summarize the ongoing trials both in preclinical and clinical setting regarding VHL disease management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Although genotype\/phenotype correlations have been described, there is considerable inter and intra-familiar heterogeneity in VHL disease. Genetic anticipation has been reported in VHL disease. From a clinical point of view, expert-opinion-based protocols suggest testing those patients with any blood relative of an individual diagnosed with VHL disease, those with at least 1 or more suggestive neoplasms or patients presenting with clear cell renal cell carcinoma (ccRCC) diagnosed at a less than 40 years old, and\/or multiple ccRCC. Clinical research is focused on safety and efficacy of systemic agents for patients with VHL-related ccRCC, with the aim to possibly preserve kidney function and improve patient survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>To date, preclinical and clinical research on the topic is scarce and clinical guidelines are not supported by strong validation studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mou.0000000000000950","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T11:33:31Z","timestamp":1637062411000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Von Hippel\u2013Lindau disease-associated renal cell carcinoma: a call to action"],"prefix":"10.1097","volume":"32","author":[{"given":"Alessandro","family":"Larcher","sequence":"first","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaline","family":"Rowe","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Belladelli","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fallara","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Clinical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Clinical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Capitanio","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Department of Urology, URI \u2013 Urological Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A review of Von Hippel\u2013Lindau syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J Kidney Cancer VHL"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.19.02263","article-title":"Growth rates of genetically defined renal tumors: implications for active surveillance and intervention","volume":"38","author":"Ball","year":"2020","journal-title":"J Clin Oncol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-019-0779-1","article-title":"Current status and future directions of immunotherapy in renal cell carcinoma","volume":"21","author":"Considine","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel\u2013Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","article-title":"Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management","volume":"36","author":"Maher","year":"2018","journal-title":"World J Urol"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00345-020-03574-5","article-title":"Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel\u2013Lindau syndrome: novel insights from a large consortium","volume":"39","author":"Capitanio","year":"2021","journal-title":"World J Urol"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel\u2013Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol"},{"issue":"(Suppl 4)","key":"R9-20250730","doi-asserted-by":"crossref","first-page":"S1158","DOI":"10.1016\/j.annonc.2020.08.2255","article-title":"Phase II study of the oral HIF-2a inhibitor MK-6482 for Von Hippel\u2013Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): update on RCC and non-RCC disease","volume":"31","author":"Srinivasan","year":"2020","journal-title":"Ann Oncol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40142-019-00180-9","article-title":"von Hippel\u2013Lindau disease: an update","volume":"7","author":"Maher","year":"2019","journal-title":"Curr Genet Med Rep"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1128\/MCB.00282-07","article-title":"Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations","volume":"27","author":"Li","year":"2007","journal-title":"Mol Cell Biol"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"e1006478","DOI":"10.1371\/journal.pcbi.1006478","article-title":"Genotype-phenotype relations of the von Hippel\u2013Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors","volume":"15","author":"Minervini","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/jmedgenet-2017-104882","article-title":"Evidence for genetic anticipation in von Hippel\u2013Lindau syndrome","volume":"55","author":"Aronoff","year":"2018","journal-title":"J Med Genet"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-14-0024","article-title":"Telomere shortening is associated with genetic anticipation in Chinese Von Hippel\u2013Lindau disease families","volume":"74","author":"Ning","year":"2014","journal-title":"Cancer Res"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fgene.2019.00358","article-title":"Intra-familial phenotypic heterogeneity and telomere abnormality in von Hippel\u2013Lindau disease: implications for personalized surveillance plan and pathogenesis of VHL-associated tumors","volume":"10","author":"Wang","year":"2019","journal-title":"Front Genet"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"11588","DOI":"10.1038\/ncomms11588","article-title":"Patient-specific factors influence somatic variation patterns in von Hippel\u2013Lindau disease renal tumours","volume":"7","author":"Fei","year":"2016","journal-title":"Nat Commun"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"eaay0482","DOI":"10.1126\/scisignal.aay0482","article-title":"HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species","volume":"12","author":"Nicholson","year":"2019","journal-title":"Sci Signal"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aap8411","article-title":"VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma","volume":"361","author":"Zhang","year":"2018","journal-title":"Science"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"154302","DOI":"10.1016\/j.metabol.2020.154302","article-title":"Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression","volume":"110","author":"Noh","year":"2020","journal-title":"Metabolism"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/jcm9092740","article-title":"Targeting \u03b22-adrenergic receptors shows therapeutical benefits in clear cell renal cell carcinoma from Von Hippel\u2013Lindau disease","volume":"9","author":"Albi\u00f1ana","year":"2020","journal-title":"J Clin Med"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel\u2013Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"85306","DOI":"10.18632\/oncotarget.13301","article-title":"Sunitinib for the treatment of benign and malignant neoplasms from von Hippel\u2013Lindau disease: a single-arm, prospective phase II clinical study from the PREDIR group","volume":"7","author":"Oudard","year":"2016","journal-title":"Oncotarget"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3389\/fonc.2019.01122","article-title":"The efficacy and safety of tyrosine kinase inhibitors for Von Hippel\u2013Lindau disease: a retrospective study of 32 patients","volume":"9","author":"Ma","year":"2019","journal-title":"Front Oncol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2015.65.6140","article-title":"Von Hippel\u2013Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome","volume":"34","author":"Nielsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","article-title":"Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis","volume":"70","author":"Mori","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2019.06.015","article-title":"Familial kidney cancer: implications of new syndromes and molecular insights","volume":"76","author":"Carlo","year":"2019","journal-title":"Eur Urol"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000132127.79974.3f","article-title":"The relationship between renal tumor size and metastases in patients with von Hippel\u2013Lindau disease","volume":"172","author":"Duffey","year":"2004","journal-title":"J Urol"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-5347(05)66524-X","article-title":"Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience","volume":"165","author":"Herring","year":"2001","journal-title":"J Urol"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00345-019-02650-9","article-title":"Should partial nephrectomy be considered \u2018elective\u2019 in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy","volume":"37","author":"Hamilton","year":"2019","journal-title":"World J Urol"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00345-020-03441-3","article-title":"Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease","volume":"39","author":"Chahoud","year":"2020","journal-title":"World J Urol"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0000000000000950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:06:37Z","timestamp":1753913197000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0000000000000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0000000000000950","relation":{},"ISSN":["0963-0643","1473-6586"],"issn-type":[{"value":"0963-0643","type":"print"},{"value":"1473-6586","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}